glimepiride 4 MG / pioglitazone 30 MG Oral Tablet

Known as: PIOGLITAZONE HYDROCHLORIDE 30 mg / GLIMEPIRIDE 4 mg ORAL TABLET, GLIMEPIRIDE 4MG/PIOGLITAZONE HCL 30MG TAB [VA Product], pioglitazone HCl 30 MG / glimepiride 4 MG Oral Tablet 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2014
0119932014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on… (More)
Is this relevant?
2009
2009
The phenomenon termed postconditioning, that is, brief episodes of ischemia/reperfusion at the onset of reperfusion reduce… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2002
2002
BACKGROUND To investigate whether the sulfonylurea glimepiride affects the myoprotective effects of ischemic preconditioning (IPC… (More)
Is this relevant?
2000
2000
UNLABELLED Glimepiride is a new long-acting the third generation sulfonylurea given once daily. The aim of this study was to… (More)
Is this relevant?
1996
1996
Glimepiride is a new generation sulphonylurea being prudently characterized in more than 2000 NIDDM patients. It has a short… (More)
Is this relevant?
1993
1993
The new sulfonylurea glimepiride (Hoe 490, CAS 93479-97-1) was tested in subchronic and chronic toxicity studies in dogs. Up to… (More)
Is this relevant?